Why Diabetes Research Matters More Than Ever
More than 38 million Americans live with diabetes, according to the Centers for Disease Control and Prevention, and the condition remains one of the most expensive and complex chronic diseases in the country. Behind those numbers are people who check their blood sugar multiple times a day, juggle insulin schedules, and worry about long-term complications affecting their kidneys, eyes, and heart.
The American Diabetes Association updates its Standards of Care each year based on findings from studies like these. Without volunteers stepping forward, the next generation of medications, devices, and treatment protocols would simply stall. The National Institutes of Health and major pharmaceutical companies run hundreds of active diabetes trials across the U.S. right now, covering everything from automated insulin delivery systems to once-weekly injectable therapies that could replace daily shots.
The NIH-supported TrialNet program, for instance, has been screening relatives of people with type 1 diabetes for years, trying to catch the disease early and test interventions that might delay or prevent its onset. Meanwhile, the Restoring Insulin Secretion (RISE) study continues to explore how treatments for prediabetes and type 2 diabetes might preserve the body's own insulin-producing capacity over time.
What Kinds of Diabetes Trials Are Recruiting Now
The landscape of diabetes research in the United States has shifted considerably. Where trials once focused narrowly on glucose control, many now examine weight loss alongside blood sugar management, cardiovascular outcomes, or remission strategies.
Once-weekly insulins represent one of the most active areas of investigation. A phase 3 study presented at the American Diabetes Association's Scientific Sessions compared a weekly insulin called efsitora alfa against daily glargine. After 52 weeks, the weekly formulation lowered HbA1c by 1.31%, comparable to the 1.27% reduction seen with daily injections. For people who struggle with injection adherence—and research suggests roughly one in four patients on insulin miss doses—a once-weekly option could meaningfully change daily life.
GLP-1 receptor agonists continue to dominate the pipeline, but newer combination therapies are gaining attention. One ongoing phase 3 trial compares CagriSema, an investigational combination of cagrilintide and semaglutide, against tirzepatide in people with type 2 diabetes. The study, which enrolled an estimated 1,000 participants across multiple U.S. sites, will track both blood sugar reduction and body weight changes over 68 weeks.
Automated insulin delivery systems are no longer limited to type 1 diabetes. A randomized trial published in the New England Journal of Medicine examined automated insulin delivery in adults with type 2 diabetes, and researchers at institutions like the Mayo Clinic and Stanford continue refining algorithms that adjust insulin delivery based on continuous glucose monitor readings.
Type 2 diabetes remission studies have also grown in number. One trial listed on ClinicalTrials.gov is evaluating whether adding intermittently scanned continuous glucose monitoring to a low-calorie meal replacement program plus diabetes self-management education can improve remission rates. This reflects a broader shift in the field toward asking not just "can we control diabetes?" but "can we reverse it?"
Here is a snapshot of how different categories of diabetes trials compare:
| Trial Type | Example Focus | Typical Duration | Ideal For | Potential Benefits | Considerations |
|---|
| Medication (Phase 2) | LY3938577 vs. degludec | 16-26 weeks | Type 2 on basal insulin | Early access to new drug class | Smaller participant pools, more frequent monitoring |
| Medication (Phase 3) | CagriSema vs. tirzepatide | 52-68 weeks | Type 2 on metformin ± SGLT2i | Larger safety data, closer to approval | Randomized assignment, possible placebo arm |
| Device/Technology | Automated insulin delivery | 12-24 weeks | Type 1 or insulin-dependent Type 2 | Reduced decision-making burden | Device training required, tech troubleshooting |
| Behavioral/Lifestyle | DASH diet + CGM for remission | 6-12 months | Recently diagnosed Type 2 | No medication risk, sustainable habits | Significant time commitment, dietary changes |
| Prevention/Screening | TrialNet family screening | Ongoing | Relatives of people with Type 1 | Early detection, potential delay of onset | May not receive active intervention |
Finding and Evaluating a Trial Near You
The process of locating a suitable diabetes clinical trial has become more accessible, but it still requires some legwork.
ClinicalTrials.gov remains the central federal registry. You can filter by condition (type 1 diabetes, type 2 diabetes, prediabetes, gestational diabetes), location (by state or city), and recruitment status. Many listings include direct contact information for the study coordinator. For example, Eli Lilly maintains a dedicated phone line at 1-877-CTLILLY for people inquiring about their diabetes research portfolio.
Academic medical centers in every region of the country run their own trials. The Joslin Diabetes Center in Boston, the University of California San Francisco, the Cleveland Clinic, and the Mayo Clinic in Rochester, Minnesota are among the institutions with the largest diabetes research programs. Smaller regional centers often participate as satellite sites for multicenter studies, so you do not necessarily need to live near a major research hub.
Physician referrals can open doors that online searches miss. Endocrinologists and diabetes educators frequently hear about upcoming trials through professional networks before they appear on public registries. If you have a strong relationship with your care team, let them know you are interested in research participation.
When you find a trial that looks promising, several practical questions deserve clear answers before you commit. Ask the study coordinator about the time commitment: how many in-person visits are required, how long each visit typically lasts, and whether any overnight stays are involved. Clarify which costs the study covers—most trials provide the investigational drug or device at no charge and cover study-related lab work, but travel expenses and lost wages are handled differently across studies.
What Participation Actually Looks Like
Susan, a 54-year-old teacher from Phoenix with type 2 diabetes, joined a phase 2 trial for a weekly injectable after struggling with daily insulin for three years. "I was nervous about being a guinea pig," she said, "but the informed consent process was thorough. They walked me through every risk, every blood draw, and made it clear I could leave at any time."
Her experience followed the pattern common to most diabetes trials. The screening phase involved blood work, a physical exam, and a review of her medical history to confirm she met the eligibility criteria. Once enrolled, she attended visits every two weeks during the dose-adjustment period, then monthly for maintenance. The study provided her with a continuous glucose monitor she had not previously had access to, and the data gave both her and the research team a detailed picture of how the medication affected her glucose patterns.
James, a 62-year-old veteran in San Antonio, took a different path. He enrolled in a dietary intervention study that examined whether a modified DASH eating plan combined with structured coaching could improve time-in-range for people with type 2 diabetes. "I was not interested in taking an experimental drug," he explained. "This study taught me skills I still use, and my HbA1c dropped from 8.2% to 7.1% over six months."
Compensation varies by study. Shorter trials involving a few clinic visits might offer a modest amount for time and travel, while longer, more demanding studies—particularly phase 1 trials requiring extended stays at a research facility—can provide more substantial payments. The key is understanding that compensation is not the primary reason to participate; access to care, closer monitoring, and contributing to science tend to rank higher among actual volunteers.
Addressing Common Concerns
One worry that surfaces repeatedly is the possibility of receiving a placebo instead of active treatment. In diabetes research, true placebo-controlled designs are less common than people assume. Many trials use an "active comparator" model, meaning you receive either the investigational treatment or an existing approved medication—never no treatment at all. When a placebo arm does exist, the study protocol typically includes rescue therapy provisions, so your health is not left unmanaged if your blood sugar rises.
Another concern involves the time after a trial ends. Will you lose access to a medication that was working well for you? Some sponsors offer extension studies or open-label phases where all participants can receive the active drug. Others coordinate with your regular physician to transition you back to standard care. This is worth discussing during the informed consent process.
The safety question deserves honest acknowledgment. Every clinical trial carries unknowns—that is why the research is being done. But the oversight structure in the United States is extensive. Institutional review boards at each study site review protocols before enrollment begins. Data safety monitoring boards can halt a study if concerning patterns emerge. Your own informed consent document, which you can take home and review before signing, spells out every known risk based on earlier phases of research.
Steps to Take This Week
-
Visit ClinicalTrials.gov and search "diabetes" filtered by your state and "recruiting" status. Bookmark two or three studies that match your situation.
-
Talk to your current endocrinologist or primary care provider about your interest. They may know of studies that fit your profile and can help you weigh the risks.
-
Prepare a list of your current medications, recent HbA1c results, and any diabetes-related complications before contacting a study coordinator. This saves time during the initial screening call.
-
Reach out to national networks like the TrialNet screening program if you have a family history of type 1 diabetes, or check whether the ADA's research listings include studies relevant to you.
Clinical trials are not the right answer for everyone. They require time, flexibility, and a tolerance for uncertainty that not every person with diabetes can accommodate. But for those who can, they offer something that standard care alone cannot: a direct role in building the future of diabetes treatment.
研究の知恵